Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment or related conditions
OwnerAli AKOUMinventor
Life of this patent
Estimating the term…
Abstract
The invention relates to methods, commercial packages and compositions for the diagnosis, prognostication and treatment of reproduction-associated diseases. The invention also relates to methods, commercial packages and compositions for the determination and modulation of endometrial receptivity.
Claims26
A method of assessing a reproduction-associated disease in a subject, said method comprising
- (a) determining a test level of a parameter selected from the group consisting of
- (i) MIF protein;
- (ii) MIF encoding RNA, and
- (iii) MIF activity;
- in a tissue or body fluid from said subject;
- and
- (b) comparing said test level to an established standard;
- or to a corresponding level of said parameter in a tissue or body fluid of a control subject;
- or to a corresponding level of said parameter in a tissue or body fluid obtained from said subject at an earlier time;
- wherein an increase in said test level is indicative of reproduction-associated disease.
A method of assessing endometrial receptivity in a subject, said method comprising determining, in said subject, a test level of a parameter selected from the group consisting of:
- (i) MIF protein;
- (ii) IL-1RII protein;
- (iii) MIF encoding RNA;
- (iv) IL-1RII encoding RNA;
- (v) MIF activity;
- and
- (vi) and IL-1RII activity;
- wherein said test level is indicative of endometrial receptivity.
A method of treating a reproductive-related disease in a subject, said method comprising:
- (a) administering an effective amount of an IL-1RII or an IL-1RII-related compound to said subject;
- (b) enhancing IL-1RII activity in said subject;
- (c) enhancing IL-1RII expression in a cell or tissue of said subject;
- and
- (d) any combination of (a) to (c).
A commercial package comprising means for assessing the level of a parameter selected from the group consisting of:
- (i) MIF protein;
- (ii) MIF encoding RNA;
- and
- (iii) MIF activity;
- in a tissue or body fluid;
- together with instructions for diagnosis, prognostication, or both, of reproduction-associated disease.
A commercial package comprising means for assessing the level of a parameter selected from the group consisting of:
- (i) MIF protein;
- (ii) IL-1RII protein;
- (iii) MIF encoding RNA;
- (iv) IL-1RII encoding RNA;
- (v) MIF activity;
- and
- (vi) IL-1RII activity;
- in a tissue or body fluid, together with instructions for the determination of the endometrial receptivity.
A commercial package comprising an IL-1RII or an IL-1RII related compound together with instructions for treating a reproductive-related disease in a subject.
A method for lowering endometrial receptivity in a subject, said method comprising administering an effective amount of an IL-1RII or IL-1RII related compound to said subject.
A commercial package comprising an IL-1RII or an IL-1RII related compound together with instructions for lowering endometrial receptivity in a subject.
Dependencies are inferred from the claim text.